Because of the scarcity of non-BRCA mutations in FPC, the clinical benefit of PARPi and other therapeutic strategies have only been focused on pancreatic cancer with BRCA1/2 mutations. The gene discussed is BRCA1; the disease is familial pancreatic carcinoma.